Healthcare Biz Review: Arena Transfers RIGHTS, Lilly Conducts Dog RESEARCH
Here are top healthcare stories to review this week:
Salix Pharmaceuticals, Ltd (NASDAQ:SLXP) shares slide and Progenics Pharmaceuticals Inc. (NASDAQ:PGNX) stocks loses more than half its value following the announcement late Friday that they have touched the FDA’s ‘third rail’: the agency requested more data on their Relistor medication for patients who have become constipated from taking opioids to treat chronic, non-cancer pain.
Don’t Miss: Clorox Fourth Quarter Earnings Sneak Peek.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) transfers the marketing rights for its Belviq diet drug to its partner Eisai Co Ltd Spons A (ESALY.PK), which will sell the pill in the United States and apply for authorization in other countries in the Western Hemisphere. SA author Red Acre Investments points out that Eisai, and not Arena, will conduct all of the pediatric and cardiovascular outcome evaluations that are mandated under Belviq’s FDA approval letter.
It appears that dogs can be specially trained to sense hypoglycemia, a dangerously low level of blood glucose, and in doing so can help avoid seizures, loss of consciousness and even death among patients suffering from diabetes, particularly Type 1. Eli Lilly and Company (NYSE:LLY) is helping to conduct research to attempt to understand how dogs can do this.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.